October's initial public offering (IPO) market remained slow last week, with only one micro-cap listing debuting on the New York Stock Exchange. The week ahead plans to bring more heat, with four companies scheduled to price, led by large biotech Prime Medicine, which would be the first larger IPO of the quarter.
Here's last week's recap:
Castellum, Inc. (NYSE: CTM) raised $3 million by pricing its NYSE American uplisting at the low end of its downwardly revised range. The company provides technology services primarily to U.S. government agencies. The stock ended the week down about 30%.
Here's listing to look out for in the week ahead:
Prime Medicine, Inc. (NASDAQ: PRME) plans to raise $184 million from 8.9 million shares priced between $16 to $18 each. The life sciences company is developing one-time curative genetic therapies using Prime Editing technology, which is believes to be more accurate and versatile than other forms of gene editing. Prime currently has 18 preclinical programs in its pipeline.
Alopexx, Inc. (NASDAQ: ALPX) plans to raise $17 million from 3 million shares priced at $5 each. The infectious disease biotech is developing immune therapies for bacterial, fungal, and parasitic infections.
Beamr Imaging Ltd. (NASDAQ: BMR) also plans to raise $17 million from 3 million shares priced at $5 each. The Israeli company provides video encoding and image optimization software, currently licensing software to enterprise customers including Netflix (NASDAQ: NFLX), ViacomCBS (NASDAQ: PARA), Microsoft (NASDAQ: MSFT) and Walmart (NYSE: WMT).
ASP Isotopes Inc. (NASDAQ: ASPI) plans to raise $16 million from 2 million shares priced between $5 to $7 each. The company has an exclusive license for the Aerodynamic Separation Process (ASP) of isotope enrichment, and focuses on the production and commercialization of enriched Molybdenum-100.
Intensity Therapeutics, Inc. (NASDAQ: INTS) plans to raise $13 million from 2 million shares priced between $4 to $5 each. The solid tumor biotech's lead candidate, INT230-6, consists of two proven anti-cancer cytotoxic agents, cisplatin and vinblastine sulfate, mixed with the amphiphilic molecule, to aid bioavailability.